2022
DOI: 10.1016/j.jddst.2022.103630
|View full text |Cite
|
Sign up to set email alerts
|

Preparation of polydopamine-modified celastrol nanosuspension and its anti-liver cancer activity in vitro

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 23 publications
0
1
0
Order By: Relevance
“…It has a significant inhibitory effect on the progression of liver tumors, 144 although its systemic toxicity, low solubility, and low bioavailability hinder its clinical application. 145–148 A glycyrrhetinic acid-modified CMCS–thioketol–rhein conjugate, developed for the delivery of celastrol (Cela/GCTR PMs), is responsive to ROS in vitro , which improves celastrol bioavailability and HCC targeting. It can effectively inhibit tumor growth and does not damage organs.…”
Section: Therapeutic Applications Of Chm-derived Nanostructuresmentioning
confidence: 99%
“…It has a significant inhibitory effect on the progression of liver tumors, 144 although its systemic toxicity, low solubility, and low bioavailability hinder its clinical application. 145–148 A glycyrrhetinic acid-modified CMCS–thioketol–rhein conjugate, developed for the delivery of celastrol (Cela/GCTR PMs), is responsive to ROS in vitro , which improves celastrol bioavailability and HCC targeting. It can effectively inhibit tumor growth and does not damage organs.…”
Section: Therapeutic Applications Of Chm-derived Nanostructuresmentioning
confidence: 99%